Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

Authors
Category Primary study
JournalBLOOD
Year 2022
This article has no abstract
Epistemonikos ID: c993b72cc637d3cd4996add72f6b17f0665fcf84
First added on: Apr 29, 2024